Article

Evidence from Mouse and Man for a Role of Neuregulin 3 in Nicotine Dependence

Department of Pharmacology, Translational Research Laboratories, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Molecular Psychiatry (Impact Factor: 14.5). 09/2013; 19(7). DOI: 10.1038/mp.2013.104
Source: PubMed

ABSTRACT

Addiction to nicotine and the ability to quit smoking are influenced by genetic factors. We used functional genomic approaches (chromatin immunoprecipitation (ChIP) and whole-genome sequencing) to identify cAMP response element-binding protein (CREB) targets following chronic nicotine administration and withdrawal (WD) in rodents. We found that chronic nicotine and WD differentially modulate CREB binding to the gene for neuregulin 3 (NRG3). Quantitative analysis of saline, nicotine and nicotine WD in two biological replicates corroborate this finding, with NRG3 increases in both mRNA and protein following WD from chronic nicotine treatment. To translate these data for human relevance, single-nucleotide polymorphisms (SNPs) across NRG3 were examined for association with prospective smoking cessation among smokers of European ancestry treated with transdermal nicotine in two independent cohorts. Individual SNP and haplotype analysis support the association of NRG3 SNPs and smoking cessation success. NRG3 is a neural-enriched member of the epidermal growth factor family, and a specific ligand for the receptor tyrosine kinase ErbB4, which is also upregulated following nicotine treatment and WD. Mice with significantly reduced levels of NRG3 or pharmacological inhibition of ErbB4 show similar reductions in anxiety following nicotine WD compared with control animals, suggesting a role for NRG3 in nicotine dependence. Although the function of the SNP in NRG3 in humans is not known, these data suggest that Nrg3/ErbB4 signaling may be an important factor in nicotine dependence.Molecular Psychiatry advance online publication, 3 September 2013; doi:10.1038/mp.2013.104.

Download full-text

Full-text

Available from: Bridgin Lee, May 12, 2014
  • Source
    • "With continual technological advancements, genetic studies have helped scientists identify common genetic variation within the human population that may underlie nicotine dependence and co-morbid disorders, such as schizophrenia. For example, SNPs on genes encoding the NRG– ErbB signaling pathway have been shown to influence nicotine dependence and withdrawal (Turner et al., 2014), as well as the pathophysiology of schizophrenia (Badner & Gershon, 2002; Gurling et al., 2001), providing researchers new insight into the potential benefits of examining the NRG–ErbB4 pathway for novel therapeutic targets not only for smoking cessation but also for treating symptoms seen in schizophrenia as well. Furthermore , due to such high demand for novel therapeutics targeted at treating co-morbid disorders such as tobacco smoking and schizophrenia, understanding common cellular processes that link these disorders is worth investigating and the NRG–ErbB pathway may represent a promising place to start. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Smoking is currently the leading cause of preventable death in the United States and is responsible for over four million deaths annually worldwide. Therefore, there is a vast clinical unmet need with regards to therapeutics targeting smoking cessation. This is even more apparent when examining smokers co-morbid with psychiatric illness, as rates of smoking in this population are ~. 4. × higher than in the general population.Examining common genetic and molecular signaling pathways impinging upon both smoking behavior and psychiatric illness will lead to a better understanding of co-morbid disorders and potential development of novel therapeutics. Studies have implicated the Neuregulin Signaling Pathway in the pathophysiology of a number of psychiatric illnesses. Additionally, recent studies have also shown an association between the Neuregulin Signaling Pathway and smoking behaviors. This review outlines basic mechanisms of the Neuregulin Signaling Pathway and how it may be exploited for precision medicine approaches in treating nicotine dependence and mental illness.
    Full-text · Chapter · Dec 2015
    • "The novelty-induced hypophagia (NIH) test was conducted as previously described A c c e p t e d M a n u s c r i p t 7 (Turner et al., 2010; Turner, Castellano, & Blendy, 2010; Turner et al., 2013; Yohn, Turner, & Blendy, 2014) with mice housed in groups of two. Mice were placed in a testing room with dividers separating their home cage, and allowed to acclimate for one hour prior to presentation of a palatable food (peanut butter chips; Nestle, Glendale, CA, USA). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nicotine withdrawal is characterized by both affective and cognitive symptoms. Identifying genetic polymorphisms that could affect the symptoms associated with nicotine withdrawal are important in predicting withdrawal sensitivity and identifying personalized cessation therapies. In the current study we used a mouse model of a non-synonymous SNP in the translated region of the BDNF gene that substitutes a valine (Val) for a methionine (Met) amino acid (Val66Met) to examine the relationship between the Val66Met SNP and nicotine dependence. This study measured proBDNF and the BDNF prodomain levels following nicotine and nicotine withdrawal and examined a mouse model of a common polymorphism in this protein (BDNF(Met/Met)) in three behavioral paradigms: novelty-induced hypophagia, marble burying, and the open-field test. Using the BDNF knock-in mouse containing the BDNF Val66Met polymorphism we found (1) blunted anxiety-like behavior in BDNF(Met/Met) mice following withdrawal in three behavioral paradigms: novelty-induced hypophagia, marble burying, and the open-field test (2) the anxiolytic effects of chronic nicotine are absent in BDNF(Met/Met) mice and (3) an increase in BDNF prodomain in BDNF(Met/Met) mice following nicotine withdrawal. Our study is the first to examine the effect of the BDNF Val66Met polymorphism on the affective symptoms of withdrawal from nicotine in mice. In these mice, a single-nucleotide polymorphism in the translated region of the BDNF gene can result in a blunted withdrawal, as measured by decreased anxiety-like behavior. The significant increase in the BDNF prodomain in BDNF(Met/Met) mice following nicotine cessation suggests a possible role of this ligand in the circuitry remodeling after withdrawal. © The Author 2015. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
    No preview · Article · Mar 2015 · Nicotine & Tobacco Research
  • [Show abstract] [Hide abstract]
    ABSTRACT: Regular smoking is the major risk factor for cardiovascular disease and cancers, and thus is one of the most preventable causes of morbidity and mortality worldwide. Intake of nicotine, its central nervous system effects, and its metabolism are regulated by biological pathways; some of these are well known, but others are not. Genetic studies offer a method for developing insights into the genes contributing to those pathways. In recent years, large genome-wide association study (GWAS) meta-analyses have consistently revealed that the strongest genetic contribution to smoking-related traits comes from variation in the nicotinic receptor subunit genes. Many other genes, including those coding for enzymes involved in nicotine metabolism, also have been implicated. However, the proportion of phenotypic variance explained by the identified genetic variants is very modest. This review intends to cover progress made in genetics and genetic epidemiology of smoking behavior in recent years, and focuses on studies revealing the nicotinic receptor gene cluster on chromosome 15q25. Evidence supporting the involvement of a novel pathway in the shared pathophysiology of nicotine dependence and schizophrenia is also briefly reviewed. A summary of the current knowledge on gene–environment interactions involved in smoking behavior is included.
    No preview · Article · Mar 2014
Show more